Supported Session: Resistant Hypertension in Women: Dispelling Common Myths and Recent Clinical Advances
This evaluation is for the following supported session. You can earn 0.5 credit hours upon completion of the evaluation survey.
Friday, August 18, 2023 • 3:30 PM – 4:00 PM
Resistant Hypertension in Women: Dispelling Common Myths and Recent Clinical Advances
The educational design of this activity addresses the needs of US-based healthcare professionals, including endocrinologists, cardiologists, internists, primary care clinicians, obstetricians, pharmacists, physicians, nurse practitioners, and physician assistants.
After completing this activity, the participant should be better able to:
- Define resistant hypertension and its burden in women
- Explain evidence-based approaches for the screening and diagnosis of resistant hypertension in women
- Recognize the limitations of antihypertensive pharmacotherapy for resistant hypertension
- Summarize recent results with renal denervation and emerging pharmacotherapies for resistant hypertension as highlighted in pivotal clinical trials and real-world registries
- Identify comprehensive and individualized treatment options for women with resistant hypertension to optimize BP control and reduce the risk of adverse outcomes
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine
Tulane University School of Medicine
New Orleans, LA
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number JA4008073-9999-23-193-L01-P. Type of activity: Knowledge
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is a registration fee for participating and receiving CME/CE credit for this educational activity. Registration information can be found here.
HOW TO REQUEST CE CREDIT
Learners may earn up to a maximum of 11.75 AMA/ACPE/ANCC credits for attending all General Sessions (earn up to 9.25 hours) and CME Satellite Sessions (earn up to 2.5 hours). To receive credit, learners must complete an evaluation available after the meeting on Saturday, August 19. The evaluation deadline has been extended to Friday, September 1, 2023 at 11:59 pm EDT. Several email reminders will be sent post-meeting.
For Pharmacists: Please allow 2-3 weeks after the deadline for your credit to be submitted to the CPE Monitor. For questions regarding the evaluation, please contact firstname.lastname@example.org
Information on planner and faculty disclosures will be available by August 17 and can be viewed here.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation